Scg3 might be a target for the treatment of diabetic eye dis

This forum will be a place for listing other useful molecular biology-related web portals and/or site announcements.

Moderator: Suzanne

Scg3 might be a target for the treatment of diabetic eye dis

Postby whbio » Mar 23 2017 2:34 pm

Over time, diabetes can cause a wide range of complications, such as retinopathy. Diabetic retinopathy, or called diabetic eye disease, is a leading cause of blindness and vision loss. In the USA, about 16 million people have diabetes and nearly 8 million have some form of diabetic retinopathy.

High blood sugar from diabetes can cause damage to the tiny blood vessels in the retina, the light-sensitive lining at the back of the eye. Diabetic retinopathy occurs when these tiny blood vessels leak blood and other fluids, causing the retinal tissue to swell and thus resulting in cloudy or blurred vision.

Previous studies have shown that vascular endothelial growth factor (VEGF) -- a potent angiogenic and vascular permeability factor -- plays a role in the pathogenesis of diabetic retinopathy. Anti-VEGF therapy represents one treatment option for the disease but it has limited efficacy.

Now a new study published in The Journal of Experimental Medicine reveals that a protein called Secretogranin III (or Scg3) can induce the formation of abnormal blood vessels in the eyes of diabetic mice, providing a potential drug target for diabetic retinopathy.

The study, led by University of Miami School of Medicine, University of Nevada Las Vegas, and Baylor College of Medicine, indicates that blocking Scg3 could protect against vision loss in diabetics as well as in premature infants.

To identify additional molecules that regulate the behavior of blood vessels, the researchers applied a new technology of comparative ligandomics to diabetic and control mice. They found that the protein Scg3 efficiently bound to the surface of retinal blood vessel cells in diabetic but not healthy mice. Moreover, Scg3 increased vascular leakage and administering it to mice stimulated blood vessel growth in diabetic but not healthy mice.

The researchers also found that VEGF bound to and induced angiogenesis in both diabetic and normal vasculature. Finally, Scg3-neutralizing antibodies significantly decreased retinal vascular leakage in diabetic mice. Collectively, the results suggest that Scg3 is a promising target for diabetic retinopathy.

By the way, Cusabio offers VEGF, cg3, and other proteins as well as antibodies. Link:
Posts: 68
Joined: Nov 02 2016 3:19 pm

Return to Other Web Portals and Sites

Who is online

Users browsing this forum: No registered users and 1 guest